Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Výzkumná studie o tom, jak dobře pro vás Concizumab funguje, pokud máte hemofilii A nebo B s inhibitory nebo bez nich (Explorer10)

17. září 2026 aktualizováno: Novo Nordisk A/S

Otevřená studie zkoumající účinnost, bezpečnost a farmakokinetiku profylaxe concizumabem u dětí mladších 12 let s hemofilií A nebo B s inhibitory nebo bez nich

This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.

Participants will have to inject the study medicine every day under the skin with a pen-injector.

The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.

Přehled studie

Postavení

Aktivní, ne nábor

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

153

Fáze

  • Fáze 3

Rozšířený přístup

Již není k dispozici mimo klinické hodnocení. Viz rozšířený záznam o přístupu.

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Algiers, Alžírsko, 16000
        • Haematology and Blood Bank Department
      • Constantine, Alžírsko, 25000
        • CHU Constantine BEN BADIS/ Hematology department
      • Banja Luka, Bosna a Hercegovina, 78000
        • University Clinical Center of Republic Srpska (545)
      • Tuzla, Bosna a Hercegovina, 75000
        • University Clinical Centre Tuzla
      • Plovdiv, Bulharsko, 4002
        • UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
      • Sofia, Bulharsko, 1527
        • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
      • Varna, Bulharsko, 9010
        • UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
      • Tallinn, Estonsko, 13419
        • Tallinn Children's Hospital
      • Chambéry, Francie, 73000
        • Centre Hospitalier Metropole Savoie
      • Le Kremlin-Bicêtre, Francie, 94275
        • Ap-Hp-Hopital de Bicetre-1
      • Paris, Francie, 75015
        • AP-HP-HOPITAL NECKER_Service d'hématologie
    • Assam
      • Guwahati, Assam, Indie, 781032
        • Guwahati Medical College
    • Gujarat
      • Surat, Gujarat, Indie, 395002
        • Nirmal Hospital Pvt. Ltd.
    • Maharashtra
      • Kolhāpur, Maharashtra, Indie, 416005
        • SSSH_Dept. of Clinical Haematology & Haemato Oncology
      • Mumbai, Maharashtra, Indie, 400012
        • Seth GS Medical College & KEM Hospital
      • Mumbai, Maharashtra, Indie, 400022
        • K.J Somaiya Hospital and Research Centre
      • Mumbai, Maharashtra, Indie, 400066
        • MCGM - Comprehensive Thalassemia Care
      • Pune, Maharashtra, Indie, 411004
        • Sahyadri Super Speciality Hospital
    • Odisha
      • Cuttack, Odisha, Indie, 753007
        • S.C.B. Medical College
    • Rajasthan
      • Jaipur, Rajasthan, Indie, 302004
        • J K Lon Hospital
    • Uttar Pradesh
      • Noida, Uttar Pradesh, Indie, 201303
        • Post Graduate Institute of Child Health
    • Uttart Pradesh
      • Lucknow, Uttart Pradesh, Indie, 226014
        • SGPGI
      • Catania, Itálie, 95123
        • A.O.U policlinico "G. Rodolico-San Marco"
      • Florence, Itálie, 50134
        • Dipartimento di Ematologia Univ. Firenze
      • Padova, Itálie, 35128
        • Azienda Ospedaliera di Padova _
      • Parma, Itálie, 43126
        • Azienda Ospedaliera-Universitaria Parma
      • Kanagawa, Japonsko, 216-8511
        • St. Marianna University School of Medicine Hospital_Pediatrics
      • Saitama, Japonsko, 330-8777
        • Saitama Children's Med Centre_Hematology-Oncology
    • Gauteng
      • Parktown, Johannesburg, Gauteng, Jižní Afrika, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • BC Children's Hospital
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • McMaster Children's Hospital
      • Beirut, Libanon, 961
        • Saint George Hospital University Medical Center
      • Tripoli, Libanon, 1434
        • Hospital Nini
      • Vilnius, Litva, LT-08406
        • Centre of Oncology and Hematology, Vilnius University
    • Kuala Lumpur
      • Kampung Baru, Kuala Lumpur, Malajsie, 50300
        • Hospital Tunku Azizah
    • Pulau Pinang
      • George Town, Pulau Pinang, Malajsie, 10450
        • Hospital Pulau Pinang
    • Sarawak
      • Kuching, Sarawak, Malajsie, 93586
        • Sarawak General Hospital
    • Terengganu
      • Kuala Terengganu, Terengganu, Malajsie, 20400
        • Hospital Sultanah Nur Zahirah
      • Oslo, Norsko, 0372
        • Klinisk forskningspost
      • Gdansk, Polsko, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Lublin, Polsko, 20-093
        • Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
      • Warsaw, Polsko, 02-091
        • Uniwersyteckie Centrum Kliniczne WUM
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polsko, 50-556
        • Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
      • Bucharest, Rumunsko, 022328
        • Clinic of Haematology, Fundeni Clinical Institute
      • Cluj-Napoca, Rumunsko, 400177
        • Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
      • Oradea, Rumunsko, 410469
        • Spitalul Clinic Judetean De Urgenta Bihor
      • Skopje, Severní Makedonie, 1000
        • PHI University Clinic for Children's Diseases Skopje
      • Birmingham, Spojené království, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Spojené království, BS2 8BJ
        • University Hospitals Bristol & Weston NHS Foundation Trust
      • London, Spojené království, WC1N 3HR
        • Great Ormond Street Hospital for Children
      • London, Spojené království, SE1 7EH
        • Evelina London Children's Hospital - Haemophilia
    • California
      • San Diego, California, Spojené státy, 92123
        • Rady Childrens Hosp San Diego
    • Colorado
      • Aurora, Colorado, Spojené státy, 80045
        • University of Colorado Hospital
    • Florida
      • Orlando, Florida, Spojené státy, 32806
        • Arnold Palmer Children's Hospital
      • Orlando, Florida, Spojené státy, 32827
        • Nemours Child Orlando Hem/Onc.
    • Georgia
      • Augusta, Georgia, Spojené státy, 30912
        • Augusta Univ/Childrens Hosp-GA
      • Savannah, Georgia, Spojené státy, 31404
        • Memorial Health University Medical Center
    • Illinois
      • Chicago, Illinois, Spojené státy, 60611
        • Childrens Hospital of Chicago
    • Indiana
      • Indianapolis, Indiana, Spojené státy, 46260
        • Indiana Hemophilia-Thromb Ctr
    • Louisiana
      • New Orleans, Louisiana, Spojené státy, 70121
        • Ochsner Clinic Foundation
      • New Orleans, Louisiana, Spojené státy, 70118
        • Children's Hosp-New Orleans
    • Missouri
      • Kansas City, Missouri, Spojené státy, 64108
        • The Children's Mercy Hospital
    • Nebraska
      • Omaha, Nebraska, Spojené státy, 68114
        • Children's Nebraska
    • North Carolina
      • Greenville, North Carolina, Spojené státy, 27834
        • ECU Sickle Cell Comp Clinic
    • Ohio
      • Columbus, Ohio, Spojené státy, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19134
        • St Christopher Hosp for Child
    • Tennessee
      • Nashville, Tennessee, Spojené státy, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Fort Worth, Texas, Spojené státy, 76104
        • Cook Children's Hospital-Hematology-Oncology
      • Houston, Texas, Spojené státy, 77030
        • Texas Children's Hospital_Houston
    • Virginia
      • Charlottesville, Virginia, Spojené státy, 22908
        • Pediatrics Hematology/Oncology Clinic Battle Building
      • Bangkok, Thajsko, 10400
        • Ramathibodi Hospital
      • Bangkok, Thajsko, 10330
        • King Chulalongkorn Memorial Hospital_Bangkok_0
      • Bangkok, Thajsko, 10700
        • Siriraj Hospital - Hematology and Oncology
      • Bangkok, Thajsko, 10330
        • King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
    • Mueang Distirct,
      • Ubon Ratchathani, Mueang Distirct,, Thajsko, 34000
        • Sunpasitthiprasong Hospital_Pediatrics Department
      • Adana, Turecko (Türkiye), 01130
        • Acibadem Adana Hastanesi
      • Adana, Turecko (Türkiye), 01130
        • Acıbadem Adana Hastanesi-Hematoloji
      • Izmir, Turecko (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi
      • Izmir, Turecko (Türkiye), 35100
        • Ege Üniversitesi Hastanesi- Hematoloji
      • Samsun, Turecko (Türkiye), 55139
        • Ondokuz Mayis University Medical Faculty Ped. Haematology
      • Samsun, Turecko (Türkiye), 55139
        • Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
    • Beşevler/Ankara
      • Ankara, Beşevler/Ankara, Turecko (Türkiye), 06500
        • Gazi University
      • Ankara, Beşevler/Ankara, Turecko (Türkiye), 06500
        • Gazi Üniversitesi Hastanesi- Hematoloji
      • Athens, Řecko, GR-11527
        • Aghia Sophia Childrens' Hospital
      • Thessaloniki, Řecko, GR 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Thessaloniki, Řecko, 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Barcelona, Španělsko, 08035
        • Hospital Vall d'Hebron
      • Madrid, Španělsko, 28046
        • Hospital Universitario La Paz
      • Málaga, Španělsko, 29009
        • Hospital Regional Universitario de Málaga
    • Murcia
      • El Palmar, Murcia, Španělsko, 30120
        • Hospital Virgen de la Arrixaca - Hematología
      • Gothenburg, Švédsko, 413 46
        • Sahlgrenska US - Koagulationscentrum

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dítě
  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

  • Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.

  • For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.

  • For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)

    1. Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    2. Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    3. Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
  • For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)

    1. Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
    2. Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
  • For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.

Exclusion Criteria:

  • Known or suspected hypersensitivity to study intervention or related products.
  • Known inherited or acquired coagulation disorder other than congenital haemophilia.
  • Ongoing or planned Immune Tolerance Induction treatment.
  • History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Concizumab-naïve patients

Concizumab-naïve participants below 12 years of age at the time of consent/assent

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Experimentální: Patients coming from compassionate use

Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of patient(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: Week 32

Measured in ng/mL

Week 32
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: Week 32

Measured in nM

Week 32
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: Week 32

Measured in ng/mL

Week 32
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: Prior to the concizumab administration at week 20

Measured in ng/mL

Prior to the concizumab administration at week 20
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Časové okno: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng*hr/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Ředitel studie: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

24. března 2022

Primární dokončení (Aktuální)

21. dubna 2026

Dokončení studie (Odhadovaný)

2. listopadu 2029

Termíny zápisu do studia

První předloženo

15. listopadu 2021

První předloženo, které splnilo kritéria kontroly kvality

15. listopadu 2021

První zveřejněno (Aktuální)

26. listopadu 2021

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • NN7415-4616
  • U1111-1247-7330 (Jiný identifikátor: World Health Organization (WHO))
  • 2020-000504-11 (Číslo EudraCT)
  • jRCT2031220097 (Identifikátor registru: JAPIC)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .